Table 2 Patient characteristics and clinical indicationsa
From: Ferumoxytol enhanced black-blood cardiovascular magnetic resonance imaging
|  | All with HASTE (n = 257) | Pre-FE HASTE (n = 121) | Post-FE HASTE (n = 229) | Pre- and post-FE HASTE (n = 93) |
|---|---|---|---|---|
Age, y | 49 (16–67) | 39 (13–65) | 48 (16–67) | 44 (16–67) |
Gender (female) | 118 (46%) | 52 (43%) | 95 (41%) | 40 (43%) |
Pre-CMR creatinine (mg/dL) | 1.9 (1.2–2.9) | 1.9 (1.0–3.0) | 1.9 (0.99–2.8) | 1.7 (0.95–2.85) |
Clinical indications | ||||
 Aneurysm /dissection | 18 (8%) | 6 (5%) | 18 (8%) | 6 (6%) |
 AVMs | 2 (1%) | 0 | 2 (1%) | 0 |
 CHD | 40 (16%) | 15 (12%) | 36 (16%) | 11 (12%) |
 Embolus /thrombus | 15 (6%) | 7 (6%) | 14 (6%) | 6 (6%) |
 Interventional planning | 28 (11%) | 16 (13%) | 26 (11%) | 14 (15%) |
 Mass | 19 (7%) | 13 (11%) | 19 (8%) | 13 (14%) |
 Other | 10 (4%) | 4 (3%) | 9 (4%) | 3 (3%) |
 Placenta | 4 (2%) | 4 (3%) | 4 (2%) | 4 (4%) |
 Post-renal transplant | 21 (8%) | 12 (10%) | 20 (9%) | 11 (12%) |
 Pre-renal transplant | 12 (5%) | 6 (5%) | 8 (3%) | 2 (2%) |
 Vascular mapping | 22 (9%) | 12 (10%) | 14 (6%) | 4 (4%) |
 Vascular thrombosis | 66 (26%) | 26 (21%) | 59 (26%) | 19 (20%) |